{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T02:31:21Z","timestamp":1792809081485,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T00:00:00Z","timestamp":1641254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Progestin-primed ovarian stimulation (PPOS) has been used in infertility cases in recent years, and several reports have stated that it has oocyte collection results similar to those of gonadotropin-releasing hormone antagonist (GnRH-ant) protocol. For emergency fertility preservation, random-start ovarian stimulation is usually recommended. Therefore we compared the clinical outcomes of random-start PPOS with those of conventional random-start GnRH-ant protocols in fertility-preserving cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We retrospectively examined 86\u2009cycles of oocyte collection, of which 56 were random-start GnRH-ant and 30 were random-start PPOS for fertility preservation at our hospital between January 2016 and April 2021. The primary outcome was the number of mature oocytes per cycle. The secondary outcome was the number of vitrified blastocysts per cycle for embryo freezing cases.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>No significant differences were noted in the number of days of stimulation, total dose of gonadotropin preparation, and the number of mature oocytes and vitrified blastocysts. The number of hospital visits for monitoring was significantly lower in the PPOS group. The start of menstruation before oocyte collection was significantly less in the PPOS group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Random-start PPOS and GnRH-ant were similar in oocyte collection results. PPOS can reduce the number of hospital visits, thus reducing patient stress. PPOS at the start of the luteal phase can prevent the start of menstruation during ovarian stimulation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13048-021-00935-5","type":"journal-article","created":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T12:02:42Z","timestamp":1641297762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Usefulness of random-start progestin-primed ovarian stimulation for fertility preservation"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-328X","authenticated-orcid":false,"given":"Haipeng","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Itaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouki","family":"Samejima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunichiro","family":"Ichinose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetaka","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Saitoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Takai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,4]]},"reference":[{"issue":"8","key":"935_CR1","doi-asserted-by":"publisher","first-page":"609","DOI":"10.2174\/1389201018666170808122531","volume":"18","author":"RB Danis","year":"2017","unstructured":"Danis RB, Pereira N, Elias RT. Random start ovarian stimulation for oocyte or embryo cryopreservation in women desiring fertility preservation prior to Gonadotoxic Cancer therapy. Curr Pharm Biotechnol. 2017;18(8):609\u201313.","journal-title":"Curr Pharm Biotechnol"},{"key":"935_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1093\/humupd\/dmr039","volume":"18","author":"AR Baerwald","year":"2012","unstructured":"Baerwald AR, Adams GP, Pierson RA. Ovarian antral folliculogenesis during the human menstrual cycle: a review. Hum Reprod Update. 2012;18:73\u201391.","journal-title":"Hum Reprod Update"},{"key":"935_CR3","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/j.fertnstert.2013.07.1992","volume":"100","author":"H Cakmak","year":"2013","unstructured":"Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100:1673\u201380.","journal-title":"Fertil Steril"},{"key":"935_CR4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1111\/jog.14267","volume":"46","author":"AS Gurbuz","year":"2020","unstructured":"Gurbuz AS, Gode F. Dydrogesterone-primed ovarian stimulation is an effective alternative to gonadotropin-releasing hormone antagonist protocol for freeze-all cycles in polycystic ovary syndrome. J Obstet Gynaecol Res. 2020;46:1403\u201311.","journal-title":"J Obstet Gynaecol Res"},{"key":"935_CR5","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1093\/humrep\/deaa068","volume":"35","author":"A La Marca","year":"2020","unstructured":"La Marca A, Capuzzo M, Sacchi S, Imbrogno MG, Spinella F, Varricchio MT, et al. Comparison of euploidy rates of blastocysts in women treated with progestins or GnRH antagonist to prevent the luteinizing hormone surge during ovarian stimulation. Hum Reprod. 2020;35:1325\u201331.","journal-title":"Hum Reprod"},{"key":"935_CR6","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/S0015-0282(00)00518-5","volume":"73","author":"DK Gardner","year":"2000","unstructured":"Gardner DK, Lane M, Stevens J, Schlenker T, Schoolcraft WB. Blastocyst score affects implantation and pregnancy outcome: towards a single blastocyst transfer. Fertil Steril. 2000;73:1155\u20138.","journal-title":"Fertil Steril"},{"key":"935_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13048-020-00620-z","volume":"13","author":"E Mathieu d'Argent","year":"2020","unstructured":"Mathieu d'Argent E, Ferrier C, Zacharopoulou C, Ahdad-Yata N, Boudy AS, Cantalloube A, et al. Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols. J Ovarian Res. 2020;13:18.","journal-title":"J Ovarian Res"},{"key":"935_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.fertnstert.2015.03.022","volume":"104","author":"Y Kuang","year":"2015","unstructured":"Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, et al. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015;104:62\u201370.","journal-title":"Fertil Steril"},{"key":"935_CR9","doi-asserted-by":"crossref","unstructured":"Chen Q, Chai W, Wang Y, Cai R, Zhang S, Lu X, Zeng X, Sun L, Kuang Y. Progestin vs. gonadotropin-releasing hormone antagonist for the prevention of premature luteinizing hormone surges in poor responders undergoing in vitro fertilization treatment: a randomized controlled trial. Front Endocrinol (Lausanne) 2019;10:796.","DOI":"10.3389\/fendo.2019.00796"},{"key":"935_CR10","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.fertnstert.2019.06.009","volume":"112","author":"S Yildiz","year":"2019","unstructured":"Yildiz S, Turkgeldi E, Angun B, Eraslan A, Urman B, Ata B. Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology. Fertil Steril. 2019;112:677\u201383.","journal-title":"Fertil Steril"},{"key":"935_CR11","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00404-018-4856-8","volume":"298","author":"N Iwami","year":"2018","unstructured":"Iwami N, Kawamata M, Ozawa N, Yamamoto T, Watanabe E, Moriwaka O, et al. New trial of progestin-primed ovarian stimulation using dydrogesterone versus a typical GnRH antagonist regimen in assisted reproductive technology. Arch Gynecol Obstet. 2018;298:663\u201371.","journal-title":"Arch Gynecol Obstet"},{"key":"935_CR12","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s10815-016-0752-y","volume":"33","author":"JD Kofinas","year":"2016","unstructured":"Kofinas JD, Mehr H, Ganguly N, Biley Y, Bochkovsky S, McCulloh D, et al. Is it the egg or the endometrium? Elevated progesterone on day of trigger is not associated with embryo ploidy nor decreased success rates in subsequent embryo transfer cycles. J Assist Reprod Genet. 2016;33:1169\u201374.","journal-title":"J Assist Reprod Genet"},{"key":"935_CR13","first-page":"846","volume":"31","author":"M Kasum","year":"2015","unstructured":"Kasum M, von Wolff M, Franulic D, \u010cehi\u0107 E, Klepac-Pulani\u0107 T, Ore\u0161kovi\u0107 S, et al. Fertility preservation options in breast cancer patients. Gynecol Endocrinol. 2015;31:846\u201351.","journal-title":"Gynecol Endocrinol"},{"key":"935_CR14","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/S0140-6736(19)31709-X","volume":"394","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"2019","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394:1159\u201368.","journal-title":"Lancet."},{"key":"935_CR15","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1093\/humrep\/dex367","volume":"33","author":"S Yu","year":"2018","unstructured":"Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, et al. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF\/ICSI cycles. Hum Reprod. 2018;33:229\u201337.","journal-title":"Hum Reprod"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00935-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-021-00935-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-021-00935-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,4]],"date-time":"2022-01-04T23:05:27Z","timestamp":1641337527000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-021-00935-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,4]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["935"],"URL":"https:\/\/doi.org\/10.1186\/s13048-021-00935-5","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,4]]},"assertion":[{"value":"10 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committees of Saitama Medical Center of Saitama Medical University (approval no. 2575). The requirement for consent for participation was waived due to the retrospective nature of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2"}}